Sunovion Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sunovion Pharmaceuticals Inc.
PODCAST: Datamonitor Healthcare analysts explore the three key psychiatric disorder markets from current market leaders to promising pipeline candidates and novel mechanisms.
Addressing health care inequities, providing a nurturing environment for employees and learning from the pandemic were among the aims expressed by executives surveyed by Scrip.
The COVID-19 pandemic drove huge shifts in clinical trial practice and the transformation is expected to continue even after the global health emergency abates. Industry leaders sharing their predictions around clinical development homed in on decentralized trials, digitization and data tools as key topics for 2022.
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
- Other Names / Subsidiaries
- Sumitomo Dainippon Pharma Co., Ltd.